UK Lung Cancer Therapeutics Market Analysis

UK Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the UK Lung Cancer Therapeutics market will reach a value of $1245 Mn from $775 Mn in 2022, growing at a CAGR of 6.1% during 2022-30.

The UK is a high-income, developed island country spanning an archipelago including Great Britain, located in Western Europe comprising England, Scotland, Wales, and Northern Ireland. After breast and prostate cancer, lung cancer is the third most frequent cancer in the UK, accounting for 13% of all new cancer cases. Every year, around 43,000 people in the UK are diagnosed with the illness.

According to the latest WHO data published in 2020 Lung Cancers Deaths in the United Kingdom reached 35,715 or 6.98% of total deaths. The age-adjusted Death Rate is 24.68 per 100,000 population ranks the United Kingdom 29^th in the world. UK's government spends 12 % of its GDP on healthcare.

Market Dynamics

Market Growth Drivers

As part of their main cancer treatment, 2% of patients with small cell lung cancer (SCLC) and 16% of patients with Non-small cell lung cancer (NSCLC) have surgery to remove the tumour. Radiotherapy is used as part of the primary cancer treatment for 42 % of patients with small cell lung cancer (SCLC) and 27 % of patients with non-small cell lung cancer (NSCLC). As part of their main cancer treatment, 68 % of patients with small cell lung cancer (SCLC) and 25 % of patients with non-small cell lung cancer (NSCLC) received chemotherapy. In lung cancer treatment, there has also been a tendency toward personalised medicine, in which treatment is tailored to the individual genetic profile of each patient's cancer.

Many patients have benefited from this method. In addition to these breakthroughs in treatment, there is a focus on improving lung cancer detection and diagnosis. Screening programmes for high-risk persons have been developed in several parts of the UK, potentially leading to earlier disease discovery and treatment. These aspects could boost the UK Lung Cancer Therapeutics market.

Market Restraints

Age and health state can both influence the type of lung cancer therapy that is most suited. Certain therapies, such as chemotherapy or radiation therapy, may not be tolerated by older individuals or those with underlying health issues. It is uncommon in people under the age of 40. More than four out of every ten persons diagnosed with lung cancer in the UK are 75 or older. It is vital to observe regulatory guidelines established by organisations such as the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) while producing new medications and therapies. These criteria can be complicated and time-consuming, resulting in delays and higher expenses. These factors may deter new entrants into the UK Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

• AstraZeneca: AstraZeneca is a British-Swedish multinational pharmaceutical company that produces several drugs for the treatment of lung cancer, including Tagrisso and Imfinzi
• GlaxoSmithKline (GSK): GSK is a British multinational pharmaceutical company that produces several drugs for the treatment of lung cancer, including Nucala and Benlysta
• Sareum Holdings: Sareum Holdings is a UK-based drug discovery and development company that focuses on developing targeted small molecule therapeutics for cancer, including lung cancer
• Scancell: Scancell is a UK-based biotechnology company that is developing innovative cancer immunotherapies for a range of cancers, including lung cancer

Recent Notable Updates

March 2023: Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine, has announced a Research Agreement with Bicycle Therapeutics, a biotechnology company pioneering a new and distinct class of therapeutics based on its proprietary bicyclic peptide technology. The Companies will research the possibilities of integrating technologies and methods to develop antigen-targeted diagnostic probes that use bicyclic peptides as their targeting mechanism and are coupled to Owlstone's Exogenous Volatile Organic Compound probes under the terms of the Agreement. The work will initially focus on lung cancer screening as a proof of principle for the larger opportunity by encouraging the selective accumulation of the probe at the tumour for higher signal and enhanced selectivity.

January 2022: Lung cancer patients will benefit from a ground-breaking new medicine on the NHS. Thanks to a contract negotiated by NHS England, thousands of lung cancer patients in England will have access to a ground-breaking new medicine that can greatly lower the chance of cancer recurring. The MHRA has officially authorised atezolizumab, an effective therapy for non-small cell lung cancer (NSCLC), with more than 850 patients in England projected to be eligible for the drug in the first year, increasing to more than 1000 in the third year.

Healthcare Policies and Reimbursement Scenarios

Lung cancer therapeutics are regulated and reimbursed in the UK by several entities, including the Medicines and Healthcare Products Regulatory Agency (MHRA), the National Institute for Health and Care Excellence (NICE), and the National Health Service (NHS). The MHRA is responsible for regulating medicines and medical devices in the UK. NICE evaluates the cost-effectiveness of lung cancer therapeutics and makes recommendations on whether they should be funded by the NHS. The local integrated care board (ICB) is involved to decide whether to support the doctor’s decision and pay for the medicine from NHS budgets.